Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the ...

A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory

Amy Parison, who stepped into the lead financial role at the company in March, is managing Editas Medicine’s transition to a new gene editing platform while recovering from a major overhaul.

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the ...

Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy

Editas Medicine (NASDAQ:EDIT) Given New $4.00 Price Target at Robert W. Baird

Editas Medicine (NASDAQ:EDIT – Get Free Report) had its target price reduced by research analysts at Robert W. Baird from $8.00 to $4.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Robert W. Baird’s price target indicates a potential upside of 189.86% from the company’s previous […]